Mark Cziraky, PharmD, CLS, explains the role of health economics and outcomes research in a payer’s decision to potentially adopt a biosimilar.
Transcript:
What is the role of health economics and outcomes research in a payer’s decision to potentially adopt a biosimilar?
I think, of course, health economics in outcomes research plays a huge role in these therapies. A lot of the benefits that are hopefully going to be seen from biosimilars are on the overall cost reductions that can be applied to the healthcare system through reduced costs of these therapies.
I think an important aspect here is taking a bit of a longer view in the use of these therapies. So again, as folks are looking at total cost of care, not just purely on the acquisition cost of the product, making sure the outcome is happening, the benefit is happening from the therapies. But clearly the reductions here with these agents are in the actual cost of the biosimilar and hopefully as more of these products enter the marketplace we’ll see more competition, and therefore we can see a better, bigger, cost-reduction in the therapies.
I think one of the challenges, of course now, in the market as well as is the fact and part of the reason why we’re just not seeing despite 10* of the therapies approved that we’re not seeing these therapies, more than 3 marketed, is there’s a lot of patent litigation going on. And there are also agreements between the manufactures, some pay-to-delay of these therapies to hit the market. So hopefully, as we can get past those issues and get more of these therapies available we’ll see the benefits in the marketplace.
*As of the date of filming
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.